Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Overview of Precigen Inc (PGEN)
Precigen Inc is a clinical stage biopharmaceutical company that develops and refines innovative gene and cell therapies using cutting-edge synthetic biology and precision technology. With proprietary platforms such as UltraCAR-T and AdenoVerse, the company designs, builds, and regulates complex gene expression programs to address intractable diseases. Its expertise in non-viral gene transfer methods and advanced DNA construction techniques positions the company as a significant innovator across multiple therapeutic areas including immuno-oncology, autoimmune disorders, and infectious diseases.
Core Business and Technological Platforms
Precigen leverages a comprehensive suite of technologies to discover and develop next generation therapeutics. The company utilizes an advanced UltraVector platform for DNA construction, facilitating the design and assembly of gene components. Its UltraCAR-T platform, which employs a non-viral Sleeping Beauty system, enables the rapid manufacturing of personalized cell therapies with an improved safety profile and simplified logistics. Additionally, the AdenoVerse platform uses a library of engineered adenovector serotypes that efficiently deliver gene therapies aimed at modulating immune responses.
Business Model and Collaborations
The business model of Precigen is centered on leveraging its proprietary technology platforms through strategic collaborations with industry experts who bring extensive development, manufacturing, and commercial capabilities. These partnerships generate revenue primarily via technology access fees, milestone payments, royalties, and reimbursement of collaborative costs. This model provides a stable framework for continuous innovation and the effective translation of preclinical discoveries into viable clinical therapies.
Market Position and Competitive Landscape
In the competitive biotechnology arena, Precigen distinguishes itself through its robust research capabilities and a diversified portfolio of therapeutic candidates. Its unique non-viral gene transfer methods and rapid manufacturing techniques set it apart from traditional gene and cell therapy developers. By focusing resources on technologies with high clinical and commercial potential, the company addresses critical unmet needs in the therapeutic landscape, thereby reinforcing its market significance.
Operational Focus and Expertise
Precigen’s operations are built on years of scientific expertise in genetic engineering and computational model integration for therapeutic design. The company’s detailed approach to tailoring gene expression programs allows for improved functional characteristics of immune cells and precise control over therapeutic outcomes. Its methodical approach and dedication to iterative clinical development underscore its commitment to advancing medicine with precision.
Summary of Value Proposition
Precigen excels in translating complex genetic information into transformative therapies with the potential to modify the disease course in challenging therapeutic areas. By continually streamlining its research and operational models, the company ensures that its innovative techniques remain at the forefront of scientific excellence and commercial relevance. The integrated approach of technology, clinical expertise, and strategic partnerships makes Precigen a notable entity within the biopharmaceutical industry.
On April 26, 2023, Precigen (Nasdaq: PGEN) announced its participation in the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago, Illinois. The company will present clinical data on two innovative therapies: PRGN-3005 UltraCAR-T for advanced, recurrent platinum-resistant ovarian cancer and PRGN-2009 AdenoVerse immunotherapy for HPV-associated cancers. Highlights include:
- PRGN-3005: Phase 1/1b study demonstrating the potential of overnight manufactured UltraCAR-T cells.
- PRGN-2009: Phase 1 study evaluating its effectiveness alone and with an anti-PDL1/TGF-Beta trap checkpoint inhibitor.
Event details and updates can be found on Precigen's investor website.
Precigen, Inc. (Nasdaq: PGEN) presented preclinical data for its next-generation UltraCAR-T platform using a mesothelin (MSLN) CAR at the AACR Annual Meeting 2023. MSLN is overexpressed in various solid tumors including mesothelioma and pancreatic cancer.
The new UltraCAR-T cells feature a novel mechanism for intrinsic PD-1 blockade, aiming to enhance safety and efficacy by eliminating the need for expensive checkpoint inhibitors. Results showed robust UltraCAR-T cell expansion and durable persistence leading to significant antitumor effects in preclinical models, even after tumor rechallenges. Collectively, these findings position the UltraCAR-T platform as a promising candidate in the cancer treatment landscape.
Precigen (NASDAQ: PGEN) has amended its license agreement with Alaunos Therapeutics, regaining exclusive rights to IL-12 gene therapy and proven CAR-T targets CD19 and BCMA. This amendment eliminates future royalties to Alaunos and enhances Precigen's ability to develop and commercialize UltraCAR-T therapies. The UltraCAR-T platform aims to deliver personalized treatments with overnight manufacturing, potentially transforming cancer therapy. The company is progressing its clinical programs for various cancers while planning a business and clinical update call on April 4, 2023.
Precigen, Inc. (NASDAQ: PGEN) announced the first patient dosing in the Phase 1/1b study of PRGN-3007, an investigational UltraCAR-T therapy targeting advanced ROR1-positive hematological and solid tumors. This innovative therapy integrates PD-1 checkpoint inhibition and aims to simplify and reduce costs associated with current treatments by eliminating the need for systemic checkpoint inhibitors. The clinical trial will enroll patients with chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma. With over 100,000 patients diagnosed in the U.S., E.U., and Japan in 2023, this development marks a significant milestone for Precigen's advanced cancer therapies.
Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Helen Sabzevari, PhD, will join a virtual fireside chat on April 4, 2023, from 10:45 AM to 11:15 AM ET at Cantor's "The Future of Oncology" Virtual Symposium.
Specializing in innovative gene and cell therapies, Precigen aims to address urgent healthcare challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Investors can find more details in the Events & Presentations section on Precigen's website.
Precigen (Nasdaq: PGEN) reported significant clinical advancements in its UltraCAR-T® and AdenoVerse™ therapies for 2022. The company presented positive results for PRGN-2012, showing a 50% complete response rate in recurrent respiratory papillomatosis, and PRGN-3006 demonstrated a 27% objective response rate in relapsed AML patients. Precigen strengthened its balance sheet through a non-health subsidiary divesture and raised approximately $73 million in a stock offering. As of December 31, 2022, it maintained $99.7 million in cash and equivalents, providing a healthy cash runway into late 2024. Total revenues increased by 89% year-over-year, but losses from continuing operations were $79.8 million.
Precigen, Inc. (Nasdaq: PGEN) has successfully closed its underwritten public offering of 42,857,143 shares of common stock at a price of $1.75 per share. The offering generated gross proceeds of approximately $75.0 million before expenses. J.P. Morgan Securities LLC and Cantor Fitzgerald & Co. were the lead managers. The offering was made under an effective shelf registration statement filed with the SEC. Precigen focuses on advancing gene and cell therapies targeting various diseases, including cancer and autoimmune disorders, emphasizing the development of affordable biotherapeutics.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What is the primary focus of Precigen Inc?
How does Precigen generate revenue?
What distinguishes Precigen's technological platforms?
Which therapeutic areas does Precigen target?
How is Precigen positioned in the competitive biotechnology landscape?
What role do partnerships play in Precigen's business model?
